The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kovalenko I.A.

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

Kruglova L.S.

Central State Medical Academy of Department of Presidential Affairs

Shatokhina E.A.

Central State Medical Academy of Administrative Directorate of the President of the Russian Federation

Current views on the mechanisms of development and pharmacotherapy of pruritus

Authors:

Kovalenko I.A., Kruglova L.S., Shatokhina E.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(1): 90‑96

DOI: 10.17116/klinderma20212001190

Read: 5498 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT VIEWS ON THE MECHANISMS OF DEVELOPMENT AND PHARMACOTHERAPY OF PRURITUS
CURRENT VIEWS ON THE MECHANISMS OF DEVELOPMENT AND PHARMACOTHERAPY OF PRURITUS

To cite this article:

Kovalenko IA, Kruglova LS, Shatokhina EA. Current views on the mechanisms of development and pharmacotherapy of pruritus. Russian Journal of Clinical Dermatology and Venereology. 2021;20(1):90‑96. (In Russ.)
https://doi.org/10.17116/klinderma20212001190

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
«Cytokine storm» as an immu­nopathologic reaction in pregnant women in the first trimester. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):19-24
Treatment of acute postoperative pain and prevention of chro­nic postoperative pain syndrome. Piro­gov Russian Journal of Surgery. 2024;(12):81-86
Study of serum cyto­kine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):25-29
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Diseases of the upper gastrointestinal tract in pregnancy: what should the gastroenterologist consider?. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):30-42
Serum cyto­kines in patients with brain tumor unde­rgoing unco­mplicated and complicated postoperative period. Russian Journal of Anesthesiology and Reanimatology. 2025;(4):21-30
Search for info­rmative predictors of the deve­lopment and progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):124-130
Abstract:

Pruritus is an extremely common symptom of various diseases, significantly reducing patients’ quality of life. According to a 2016 European study, the symptom was present in 54.4% of patients seen for skin pathology. Characterized by a wide range of etiopathogenetic mechanisms of development, pruritus ultimately leads to a significant reduction in the quality of life of patients. This symptom affects sensory, emotional, and cognitive aspects of life, which makes it urgent to further study the mechanisms of skin pruritus and develop modern aspects of therapy. Modern ideas about the main pathogenetic pathways of skin pruritus formation are analyzed: violation of the epidermal barrier, the role of humoral factors and neuronal sensitization. The role of dermal interleukins, opioids and a number of intracellular mediators in the formation of itching is considered separately. Data on pathogenetic pathways of pruritus are summarized and a review of pharmacotherapy on the basis of current data is given. The need for an integrated approach to the therapy of pruritus is emphasized, aimed both at eliminating the main etiopathogenetic factor and at preventing the formation of a vicious circle of allodynia, leading to chronicity of the symptom and a significant reduction in the quality of life of patients. The choice of optimal pharmacotherapy tactics for patients with pruritus is a relevant aspect of the clinical activity of physicians of various specialties.

Keywords:

pruritus
pharmacotherapy
epidermal barrier
histamine
interleukins
allodynia

Authors:

Kovalenko I.A.

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

Kruglova L.S.

Central State Medical Academy of Department of Presidential Affairs

Shatokhina E.A.

Central State Medical Academy of Administrative Directorate of the President of the Russian Federation

Received:

19.01.2020

Accepted:

23.11.2020

Close metadata

References:

  1. Weisshaar E. Epidemiology of Itch. Curr Probl Dermatol. 2016;50:5-10.  https://doi.org/10.1159/000446010
  2. Weisshaar E, Dalgard F. Epidemiology of itch: Adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89(4):339-350.  https://doi.org/10.2340/00015555-0662
  3. Erturk IE, Arican O, Omurlu IK, Sut N. Effect of the Pruritus on the Quality of Life: A Preliminary Study. Ann Dermatol. 2012;24(4):406-412.  https://doi.org/10.5021/ad.2012.24.4.406
  4. Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147(10):1153-1156. https://doi.org/10.1001/archdermatol.2011.178
  5. Dermatologiya Fitspatrika v klinicheskoi praktike. Izdanie vtoroe. In: Potekaeva N.N., Lvov A.N., Adaskevich V.P., Romanov D.V. M.: Panfilova; 2019. (In Russ.).
  6. Nicholas K, Mollanazar K, Smith P, Yosipovitch G Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? Clinic Rev Allerg Immunol. 2016;51:263-292.  https://doi.org/10.1007/s12016-015-8488-5
  7. Elmariah S. Adjunctive Management of Itch in Atopic Dermatitis. Dermatol Clin. 2017;35(3):373-394.  https://doi.org/10.1016/j.det.2017.02.011
  8. Yasutomo I. Interleukin-33 in atopic dermatitis. J Dermatol Sci. 2019;96(1):2-7.  https://doi.org/10.1016/j. jdermsci.2019.08.006
  9. Du L, Hu X, Yang W, Yasheng H, Liu S, Zhang W, Zhou Y, Cui W, Zhu J, Qiao Z, Maoying Q, Chu Y, Zhou H, Wang Y, Mi W Spinal IL-33/ST2 signaling mediates chronic itch in mice through the astrocytic JAK2-STAT3 cascade. Glia. 2019;67(9):1680-1693. https://doi.org/10.1002/glia.23639
  10. Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: An update (Review). Experimental and therapeutic medicine. 2019;17:1061-1067. https://doi.org/10.3892/etm.2018.6989
  11. Mochizuki H, Schut C, Nattkemper L, Yosipovitch G. Brain mechanism of itch in atopic dermatitis and its possible alteration through non-invasive treatments. Allergology International. 2017;66(1):14-21.  https://doi.org/10.1016/j.alit.2016.08.013
  12. Hassan I, Haji ML. Understanding itch: An update on mediators and mechanisms of pruritus. Indian J Dermatol Venereol Leprol. 2014;80(2):106-114.  https://doi.org/10.4103/0378-6323.129377
  13. Farmer WS, Marathe KS. Atopic Dermatitis: Managing the Itch. Adv Exp Med Biol. 2017;1027:161-177.  https://doi.org/10.1007/978-3-319-64804-0_13
  14. Saleem MD, Oussedik E, D’Amber V, Feldman SR. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599.  https://doi.org/10.1080/09546634.2017.1290205
  15. Petronelli M. Breakthrough therapy designation granted to nemolizumab for pruritus. Dermatology Times. Acessed December 9, 2019. https://www.dermatologytimes.com/biologics/breakthrough-therapy-designation-granted-nemolizumab-pruritus
  16. Pereira MP, Mittal A, Ständer S. Current treatment strategies in refractory chronic pruritus. Curr Opin Pharmacol. 2019;46:1-6.  https://doi.org/10.1016/j.coph.2018.11.007
  17. Klinicheskie rekomendatsii po profilaktike i lecheniyu toshnoty i rvoty u bol’nykh, poluchayushchikh khimio- i luchevuyu protivoopukholevuyu terapiyu. M. 2014. Accessed January 13, 2020. (In Russ.). https://www.oncology.ru/association/clinical-guidelines/2014/49.pdf
  18. Alice He, Alhariri JM, Sweren RJ, Kwatra MM, Kwatra SG. Aprepitant for the Treatment of Chronic Refractory Pruritus. Biomed Res Int. 2017;2017: 4790810. https://doi.org/10.1155/2017/4790810
  19. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Dupiksent Accessed January 13, 2020 (In Russ.). https://www.sanofi.ru/-/media/Project/One-Sanofi-Web/Websites/Europe/Sanofi-RU/Home/healthcare-solutions/immunology/Dupixent_04042019.pdf
  20. Misery L, Huet F, Gouin O, Sta S, Deleuran M. Current pharmaceutical developments in atopic dermatitis. Curr Opin Pharmacol. 2019;46:7-13.  https://doi.org/10.1016/j.coph.2018.12.003
  21. Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, van der Merwe R. Tezepelumab an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013-1021. https://doi.org/10.1016/j.jaad.2018.11.059
  22. Psoriaz, klinicheskie rekomendatsii, 2016 Accessed January 13, 2020. (In Russ.). https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2017/%D0%9F%D0%B8%D0%BE%D0%B4%D0%B5%D1%80%D0%BC%D0%B8%D0%B8.%D0%9A%D0%A0232.docx
  23. Yosipovitch G, Rosen JD, BS, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375-1390. https://doi.org/10.1016/j.jaci.2018.09.005
  24. Lvov AN, Bobko SI, Romanov DV. Somatophorm and amplified itch. Russian Journal of Skin and Sexually Transmitted Diseases. 2013;4:39-43. (In Russ.).
  25. Sheriff T, Lin MJ, Dubin D, Khorasani H. The potential role of cannabinoids in dermatology. J Dermatolog Treat. 2019;10:1-7.  https://doi.org/10.1080/09546634.2019.1675854
  26. Lee YW, Won CH, Jung K, Nam HJ, Choi G, Park YH, Park M, Kim B. Br Efficacy and safety of PAC-14028 cream — a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. J Dermatol. 2019;180(5):1030-1038. https://doi.org/10.1111/bjd.17455
  27. Fawaz B, Chamseddin BH, Griffin JR. Defining the role of mirtazapine in the treatment of refractory pruritus. J Dermatolog Treat. 2019;27:1-5.  https://doi.org/10.1080/09546634.2019.1630702
  28. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H. Involvement ofcentral mu-opioid system in the scratching behavior inmice and the suppression of it by the activation ofkappa-opioid system. Eur J Pharmacol. 2003;477:29-35.  https://doi.org/10.1016/j.ejphar.2003.08.007
  29. Inagaki N, Shiraishi N, Igeta K, Nagao M, Kim JF, Chikumoto T, Itoh T, Katoh H, Tanaka H, Nagai H. Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus. Eur J Pharmacol. 2010;25;626(2-3):283-289.  https://doi.org/10.1016/j.ejphar.2009.09.043
  30. Oswald K. Atopic dermatitis: dupilumab and crisaborole could herald a new era in treatment. The Pharmaceutical Journal. Accepted February 23, 2017. https://www.pharmaceutical-journal.com/news-and-analysis/features/atopic-dermatitis-dupilumab-and-crisaborole-could-herald-a-new-era-in-treatment/20202337.article
  31. Hoy SM. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol. 2017;18(6):837-843.  https://doi.org/10.1007/s40257-017-0327-4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.